Events Partner Content 3rd Chronic Kidney Disease Drug Development (CKD3) Summit Advance Therapeutics for Chronic Kidney Diseases
Events Partner Content 3rd Chronic Kidney Disease Drug Development (CKD3) Summit Advance Therapeutics for Chronic Kidney Disease
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
